• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

The following list of names for the drugs described are "under consideration" by the USAN Council:

December 2014

andepatuzumab treatment of cancer
erenumab prevention of migraine
olizeridine treatment of pain
pibrentasvir treatment of HCV infection
porticeridine treatment of pain
suclalizumab treatment of idiopathic pulmonary fibrosis
torvapasvir treatment of HCV infection
vistinumab prevention of migraine

November 2014

burisumab treatment of X-linked hypophosphatemia
flortaucipir brain diagnostic imaging agent
flortaupazine brain diagnostic imaging agent
padacitinib treatment of antineoplastic

October 2014

bertalzumab treatment of amyloidosis
domeglivant treatment of diabetes